SeaCrest Wealth Management LLC Has $11 Million Stock Position in Eli Lilly and Company $LLY

Key Points

• SeaCrest Wealth Management LLC decreased its holdings in Eli Lilly and Company by 12.0%, owning 14,108 shares valued at approximately $10.99 million as of the latest filing.
• Several analysts have recently downgraded their ratings on Eli Lilly, with Wall Street Zen lowering the rating from "strong-buy" to "buy" and price targets adjusted down to a consensus target of $939.61.
• Eli Lilly announced a quarterly dividend of $1.50 per share, representing a 0.8% yield, with a payout ratio of 39.22%.

SeaCrest Wealth Management LLC lessened its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 12.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,108 shares of the company's stock after selling 1,932 shares during the quarter. Eli Lilly and Company accounts for approximately 1.2% of SeaCrest Wealth Management LLC's portfolio, making the stock its 12th largest holding. SeaCrest Wealth Management LLC's holdings in Eli Lilly and Company were worth $10,997,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. WestEnd Advisors LLC raised its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department grew its holdings in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the first quarter valued at $40,000. Finally, TD Capital Management LLC raised its position in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after acquiring an additional 31 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock traded down $9.41 during trading hours on Friday, hitting $753.52. 7,319,147 shares of the stock traded hands, compared to its average volume of 3,181,974. Eli Lilly and Company has a one year low of $623.78 and a one year high of $939.86. The company has a market cap of $713.18 billion, a P/E ratio of 49.25, a P/E/G ratio of 1.05 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a 50-day simple moving average of $738.37 and a 200 day simple moving average of $770.79.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's payout ratio is presently 39.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LLY shares. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their price objective for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Insider Activity

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.